http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 12 Jul 2026 20:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), <span id="spanHghlt7244">and</span> China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, <span id="spanHghlt2564">today</span> announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.</p> <p>According to the collaboration agreement, the two parties will jointly advance the co-development of the R&amp;D program by combining <span value="ACORN:5021693578" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Deepening+Collaboration+in+AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+additional+collaborations+in+CNS+diseases/26758632.html Sun, 12 Jul 2026 20:30:00 -0400 3696 867 A.50210275 A.50216935 O.31525930 O.57690994 O15 SGX http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/Press+Releases/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/PRNewswire/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/PRNewswire/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/PRNewswire/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/PRNewswire/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX http://www.streetinsider.com/PRNewswire/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <span class="legendSpanClass"><chron>Feb. 10, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</p> <p>According to the collaboration agreement, the two parties will combine Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&amp;D team and deep disease-area expertise http://www.streetinsider.com/PRNewswire/AI-Powered+R%26amp%3BD+Acceleration%3A+Insilico+Medicine+and+CMS+announce+multiple+collaborations+in+central+nervous+system+and+autoimmune+diseases/25971524.html Tue, 10 Feb 2026 08:00:00 -0400 3696 867 A.50210275 O.31525930 O15 SGX